AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Novobiocin is effective against certain Gram-positive bacteria, including Staphylococcus aureus and Staphylococcus epidermidis. It works by inhibiting bacterial DNA gyrase, an enzyme essential for DNA replication, thereby preventing bacterial growth and proliferation. Novobiocin may be prescribed to treat infections such as skin and soft tissue infections, urinary tract infections, and certain types of pneumonia caused by susceptible bacteria.
Methicillin-Resistant Staphylococcus aureus (MRSA): Novobiocin may be used in the treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) strains that are susceptible to this antibiotic. MRSA infections can be challenging to treat due to their resistance to many commonly used antibiotics, and novobiocin may be considered as an alternative treatment option in some cases.
Bacterial Endocarditis Prophylaxis: In some cases, novobiocin may be used prophylactically to prevent bacterial endocarditis, a serious infection of the heart lining or valves, in individuals at high risk, such as those with certain congenital heart defects or a history of bacterial endocarditis. However, the use of novobiocin for endocarditis prophylaxis is less common compared to other antibiotics such as penicillin or amoxicillin.
Other Infections: Novobiocin may also be used to treat other bacterial infections not mentioned here, depending on the susceptibility of the causative bacteria and the judgment of the healthcare provider.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 3.5 | -0.03 |
| Allergies | 7.5 | 4.3 | 0.74 |
| Allergy to milk products | 2.6 | 1.6 | 0.63 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.5 | 8.3 | -0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.5 | 1.87 |
| Ankylosing spondylitis | 5.3 | 1.8 | 1.94 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 6.5 | 3.4 | 0.91 |
| Atherosclerosis | 2.7 | 2.4 | 0.13 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11.9 | 11.9 | 0 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.6 | 4.3 | -0.19 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 6.6 | 7.7 | -0.17 |
| Chronic Kidney Disease | 5.2 | 3.4 | 0.53 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 2 | 0.5 |
| Chronic Urticaria (Hives) | 2 | 1.8 | 0.11 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 8.9 | 2.8 | 2.18 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 12.1 | 14.9 | -0.23 |
| Crohn's Disease | 10.4 | 6.9 | 0.51 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 3.2 | 1.4 | 1.29 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 14 | 11.6 | 0.21 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.6 | -0.13 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.5 | 2.8 | 0.61 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.3 | 1.6 | 1.69 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.9 | 2.5 | 0.56 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.6 | 1 | 1.6 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
| Heart Failure | 5.4 | 2.4 | 1.25 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.6 | 0.83 |
| hyperglycemia | 3 | 2.2 | 0.36 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.8 | 6.8 | -0.17 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 4.1 | 0.3 | 12.67 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 10.9 | 12.1 | -0.11 |
| Insomnia | 2.5 | 3.5 | -0.4 |
| Intelligence | 2 | 0.6 | 2.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 10 | 6.4 | 0.56 |
| ischemic stroke | 3.2 | 1.7 | 0.88 |
| Liver Cirrhosis | 9.2 | 5.9 | 0.56 |
| Long COVID | 8.7 | 9.3 | -0.07 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 9.5 | 9.6 | -0.01 |
| Mood Disorders | 14 | 9.5 | 0.47 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 9 | 7 | 0.29 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 2.2 | -0.83 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.5 | 5.9 | 0.1 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 12.8 | 10.6 | 0.21 |
| obsessive-compulsive disorder | 7 | 4.8 | 0.46 |
| Osteoarthritis | 3.3 | 1.7 | 0.94 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 10.6 | 8.3 | 0.28 |
| Polycystic ovary syndrome | 7.9 | 3.7 | 1.14 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4.4 | 4 | 0.1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.6 | 4.7 | 1.04 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.8 | 3.6 | 1.17 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.6 | 2.67 |
| Stress / posttraumatic stress disorder | 3.7 | 3.3 | 0.12 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 5.1 | 4.4 | 0.16 |
| Type 2 Diabetes | 10.5 | 9 | 0.17 |
| Ulcerative colitis | 7 | 8.8 | -0.26 |
| Unhealthy Ageing | 6.8 | 2.9 | 1.34 |
| Vitiligo | 2.5 | 2 | 0.25 |
